Department of Biomedical Engineering and Physics, Amsterdam University Medical Center, location AMC, Amsterdam, the Netherlands.
Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, the Netherlands.
JAMA Neurol. 2019 Feb 1;76(2):194-202. doi: 10.1001/jamaneurol.2018.3661.
The positive treatment effect of endovascular therapy (EVT) is assumed to be caused by the preservation of brain tissue. It remains unclear to what extent the treatment-related reduction in follow-up infarct volume (FIV) explains the improved functional outcome after EVT in patients with acute ischemic stroke.
To study whether FIV mediates the relationship between EVT and functional outcome in patients with acute ischemic stroke.
DESIGN, SETTING, AND PARTICIPANTS: Patient data from 7 randomized multicenter trials were pooled. These trials were conducted between December 2010 and April 2015 and included 1764 patients randomly assigned to receive either EVT or standard care (control). Follow-up infarct volume was assessed on computed tomography or magnetic resonance imaging after stroke onset. Mediation analysis was performed to examine the potential causal chain in which FIV may mediate the relationship between EVT and functional outcome. A total of 1690 patients met the inclusion criteria. Twenty-five additional patients were excluded, resulting in a total of 1665 patients, including 821 (49.3%) in the EVT group and 844 (50.7%) in the control group. Data were analyzed from January to June 2017.
The 90-day functional outcome via the modified Rankin Scale (mRS).
Among 1665 patients, the median (interquartile range [IQR]) age was 68 (57-76) years, and 781 (46.9%) were female. The median (IQR) time to FIV measurement was 30 (24-237) hours. The median (IQR) FIV was 41 (14-120) mL. Patients in the EVT group had significantly smaller FIVs compared with patients in the control group (median [IQR] FIV, 33 [11-99] vs 51 [18-134] mL; P = .007) and lower mRS scores at 90 days (median [IQR] score, 3 [1-4] vs 4 [2-5]). Follow-up infarct volume was a predictor of functional outcome (adjusted common odds ratio, 0.46; 95% CI, 0.39-0.54; P < .001). Follow-up infarct volume partially mediated the relationship between treatment type with mRS score, as EVT was still significantly associated with functional outcome after adjustment for FIV (adjusted common odds ratio, 2.22; 95% CI, 1.52-3.21; P < .001). Treatment-reduced FIV explained 12% (95% CI, 1-19) of the relationship between EVT and functional outcome.
In this analysis, follow-up infarct volume predicted functional outcome; however, a reduced infarct volume after treatment with EVT only explained 12% of the treatment benefit. Follow-up infarct volume as measured on computed tomography and magnetic resonance imaging is not a valid proxy for estimating treatment effect in phase II and III trials of acute ischemic stroke.
血管内治疗 (EVT) 的积极治疗效果被认为是通过保存脑组织来实现的。但目前尚不清楚治疗相关的随访梗死体积 (FIV) 减少在多大程度上解释了急性缺血性脑卒中患者 EVT 后功能结局的改善。
研究 FIV 是否介导急性缺血性脑卒中患者 EVT 与功能结局之间的关系。
设计、地点和参与者:汇总了来自 7 项随机多中心试验的患者数据。这些试验于 2010 年 12 月至 2015 年 4 月进行,纳入了 1764 名随机分配接受 EVT 或标准治疗(对照组)的患者。在发病后通过计算机断层扫描或磁共振成像评估随访梗死体积。进行中介分析以检查 FIV 可能介导 EVT 与功能结局之间关系的潜在因果链。共有 1690 名患者符合纳入标准。排除了 25 名额外的患者,最终共有 1665 名患者纳入分析,包括 EVT 组 821 名(49.3%)和对照组 844 名(50.7%)。数据分析于 2017 年 1 月至 6 月进行。
改良 Rankin 量表(mRS)评估的 90 天功能结局。
在 1665 名患者中,中位(四分位距 [IQR])年龄为 68(57-76)岁,781 名(46.9%)为女性。FIV 测量的中位(IQR)时间为 30(24-237)小时。中位(IQR)FIV 为 41(14-120)mL。与对照组相比,EVT 组患者的 FIV 明显更小(中位数[IQR],33[11-99] vs 51[18-134]mL;P=0.007),90 天时 mRS 评分也更低(中位数[IQR],3[1-4] vs 4[2-5])。随访梗死体积是功能结局的预测因素(调整后的共同优势比,0.46;95%CI,0.39-0.54;P<0.001)。随访梗死体积部分介导了治疗类型与 mRS 评分之间的关系,因为在调整 FIV 后 EVT 与功能结局仍显著相关(调整后的共同优势比,2.22;95%CI,1.52-3.21;P<0.001)。治疗减少的 FIV 解释了 EVT 与功能结局之间 12%(95%CI,1-19)的关系。
在本分析中,随访梗死体积预测了功能结局;然而,EVT 治疗后梗死体积的减少仅解释了治疗效果的 12%。在急性缺血性脑卒中的 II 期和 III 期试验中,基于 CT 和磁共振成像测量的随访梗死体积不能作为评估治疗效果的有效替代指标。